COMP <GO>
AME vs TMO // PIOTROSKI F-SCORE QUALITY
AMETEK Inc. (NYSE) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: AME 10
— TMO 4
▲ PIOTROSKI F-SCORE QUALITY LEADER: AME
LAST: $241.12 (-4.23%) • MKT CAP: $57.72B
piotroski-score
9/9
LAST: $697.00 (-1.72%) • MKT CAP: $262.22B
piotroski-score
8/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AME VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AME | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 36.00% | 41.00% | -5.00 | TMO | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 13.40% | 9.30% | +4.10 | AME | /roic <GO> |
| EV/EBITDA & P/E Valuation | 28.9x | 30.4x | -1.50 | AME | /valuation <GO> |
| Free Cash Flow Yield | 2.90% | 2.40% | +0.50 | AME | /fcf-yield <GO> |
| Operating Margin | 25.80% | 17.40% | +8.40 | AME | /operating-margins <GO> |
| Net Profit Margin | 20.00% | 15.10% | +4.90 | AME | /net-margins <GO> |
| Revenue Growth (YoY) | 6.60% | 3.90% | +2.70 | AME | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.49% | 0.24% | +0.25 | AME | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 8.30 | 4.50 | +3.80 | AME | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 9/9 | 8/9 | +1.00 | AME | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.80% | 6.70% | +0.10 | TMO | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 44.1 | 59.1 | -15.00 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.97 | 0.94 | +0.03 | AME | /macro-sensitivity <GO> |
| Forward P/E Multiple | 36.3x | 36.3x | 0.00 | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $57.72B | $262.22B | -$204.49B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AME REV | TMO REV | AME GROSS % | TMO GROSS % | AME FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $7.40B | $44.56B | 36.0% | 44.0% | $1.67B | $6.29B |
| FY 2024 | $6.94B | $42.88B | 35.7% | 44.0% | $1.70B | $7.27B |
| FY 2023 | $6.60B | $42.86B | 44.0% | 44.0% | $1.44B | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AME // BETA 0.97
TMO // BETA 0.94